 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | GW842166 / GSK
Preclinical, Journal: A mouse model of chronic primary pain that integrates clinically relevant genetic vulnerability, stress, and minor injury. (Pubmed Central) - Apr 14, 2024
Yet, pain in the CPPC model was alleviated by the beta-3 adrenergic antagonist SR59230A. Thus, the CPPC mouse model reliably recapitulates clinically and biologically relevant features of CPPCs and may be implemented to test underlying mechanisms and find new therapeutics.
- GW842166 / GSK
A novel mouse model of chronic primary pain conditions that integrates COMT genotype and environmental stress/injury (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_13164;
Thus, our novel mouse model reliably recapitulates clinically- and biologically-relevant features of CPPCs and can be further implemented to test underlying mechanisms and discover new therapeutics. Funding: NIH/NINDS R01 NS109541 and R61/R33 NS123753 to A Nackley.
- GAO-3-02 / GAOMA Therap
Synaptamide Phosphonate-GAO-3-02-potentiates GABAergic transmission in the rat lithium-pilocarpine model of temporal lobe epilepsy via activation of CB2 receptor (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12788;
The present study suggests that GAO-3-02 enhances GABAergic transmission onto CA1 pyramidal neurons through activating CB2 receptor. Our results may provide a cellular and molecular mechanism that helps explain the anti-seizure effects of GAO-3-02 in the rat lithium-pilocarpine model of temporal lobe epilepsy.
- | GW842166 / GSK
Preclinical, Journal: GW842166X Alleviates Osteoarthritis by Repressing LPS-mediated Chondrocyte Catabolism in Mice. (Pubmed Central) - Oct 28, 2022
Our results may provide a cellular and molecular mechanism that helps explain the anti-seizure effects of GAO-3-02 in the rat lithium-pilocarpine model of temporal lobe epilepsy. GW842166X impeded the LPS-mediated catabolism in mouse chondrocytes, thereby inhibiting the progression of osteoarthritis.
- | GW842166 / GSK
Preclinical, Journal: CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice. (Pubmed Central) - Jul 29, 2022
GW842166x treatments ameliorated 6-OHDA-induced anxiogenic- and depressive-like behaviors, but the effects were blocked by CB2 antagonism, suggesting a CB2-dependent mechanism. These results suggest that the CB2 agonist GW842166x not only reduces 6-OHDA-induced motor function deficits but also anxiogenic- and depressive-like behaviors in 6-OHDA mouse models of PD.
- || GW842166 / GSK, ART27.13 / Artelo Biosci, adMare BioInnovations
Review, Journal: Cannabis and orofacial pain: a systematic review. (Pubmed Central) - Jun 29, 2022
Further research is warranted to explore and substantiate the therapeutic role of CBPMs in the context of orofacial pain and inflammation. As evidence supporting their use expands, healthcare professionals should pay close attention to outcomes and changes to legislation that may impact and potentially benefit their patients.
- | GW842166 / GSK
Preclinical, Journal: The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease. (Pubmed Central) - Jan 18, 2022
We found that the bath application of GW842166x led to a decrease in action potential firing, likely due to a decrease in hyperpolarization-activated currents (I) and a shift of the half-activation potential (V) of I to a more hyperpolarized level. Taken together, the CB2 agonist GW842166x may reduce the vulnerability of dopamine neurons to 6-OHDA by decreasing the action potential firing of these neurons and the associated calcium load.
- GW842166 / GSK
Enrollment change: A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis (clinicaltrials.gov) - Jun 26, 2017
P2, N=1, Completed, Sponsor: GlaxoSmithKline
Taken together, the CB2 agonist GW842166x may reduce the vulnerability of dopamine neurons to 6-OHDA by decreasing the action potential firing of these neurons and the associated calcium load. N=45 --> 1
- GW842166 / GSK
Enrollment change, Trial withdrawal: Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects. (clinicaltrials.gov) - Feb 19, 2015
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=45 --> 1 N=36 --> 0 | Terminated --> Withdrawn
- GW842166 / GSK
Trial withdrawal: Dose Response and Efficacy of GW842166 in Pain (clinicaltrials.gov) - Dec 17, 2014
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=36 --> 0 | Terminated --> Withdrawn Terminated --> Withdrawn